OBJECTIVE AND DESIGN: Mesenchymal stem cells (MSCs) are potent modulators of immune responses. Sepsis is the association of a systemic inflammatory response with an infection. The aim of this study was to test the ability of MSCs derived from adipose tissue, which have immunomodulatory effects, and to inhibit the septic process in an experimental model of mice. METHODS: Three experimental groups (male C57BL/6 mice) were formed for the test: control group, untreated septic group and septic group treated with MSCs (1 × 10(6) cells/animal). RESULTS: In the control group, there were no deaths; in the untreated septic group, the mortality rate was 100 % within 26 h; in the septic group treated with MSCs, the mortality rate reached 40 % within 26 h. The group treated with MSCs was able to reduce the markers of tissue damage in the liver and pancreas. The treated group had a reduction of inflammatory markers. Furthermore, the MSCs-treated group was able to inhibit the increase of apoptosis in splenocytes observed in the untreated septic group. CONCLUSIONS: Our data showed that MSCs ameliorated the immune response with decrease of inflammatory cytokines and increase anti-inflammatory IL-10; moreover, inhibited splenocytes apoptosis and, consequently, inhibited tissue damage during sepsis.
OBJECTIVE AND DESIGN: Mesenchymal stem cells (MSCs) are potent modulators of immune responses. Sepsis is the association of a systemic inflammatory response with an infection. The aim of this study was to test the ability of MSCs derived from adipose tissue, which have immunomodulatory effects, and to inhibit the septic process in an experimental model of mice. METHODS: Three experimental groups (male C57BL/6 mice) were formed for the test: control group, untreated septic group and septic group treated with MSCs (1 × 10(6) cells/animal). RESULTS: In the control group, there were no deaths; in the untreated septic group, the mortality rate was 100 % within 26 h; in the septic group treated with MSCs, the mortality rate reached 40 % within 26 h. The group treated with MSCs was able to reduce the markers of tissue damage in the liver and pancreas. The treated group had a reduction of inflammatory markers. Furthermore, the MSCs-treated group was able to inhibit the increase of apoptosis in splenocytes observed in the untreated septic group. CONCLUSIONS: Our data showed that MSCs ameliorated the immune response with decrease of inflammatory cytokines and increase anti-inflammatory IL-10; moreover, inhibited splenocytes apoptosis and, consequently, inhibited tissue damage during sepsis.
Authors: R S Hotchkiss; K W Tinsley; P E Swanson; R E Schmieg; J J Hui; K C Chang; D F Osborne; B D Freeman; J P Cobb; T G Buchman; I E Karl Journal: J Immunol Date: 2001-06-01 Impact factor: 5.422
Authors: H Bryant Nguyen; Emanuel P Rivers; Fredrick M Abrahamian; Gregory J Moran; Edward Abraham; Stephen Trzeciak; David T Huang; Tiffany Osborn; Dennis Stevens; David A Talan Journal: Ann Emerg Med Date: 2006-05-02 Impact factor: 5.721
Authors: Mauricio Rojas; Jianguo Xu; Charles R Woods; Ana L Mora; Willy Spears; Jesse Roman; Kenneth L Brigham Journal: Am J Respir Cell Mol Biol Date: 2005-05-12 Impact factor: 6.914
Authors: Ricardo Garcia Branco; Robert Charles Tasker; Pedro Celiny Ramos Garcia; Jefferson Pedro Piva; Lisandra Dias Xavier Journal: J Pediatr (Rio J) Date: 2007-11 Impact factor: 2.197
Authors: Silke M Schulz; Gabriele Köhler; Christoph Holscher; Yoichiro Iwakura; Gottfried Alber Journal: Int Immunol Date: 2008-07-03 Impact factor: 4.823
Authors: Amy V Gore; Letitia E Bible; David H Livingston; Alicia M Mohr; Ziad C Sifri Journal: J Trauma Acute Care Surg Date: 2015-10 Impact factor: 3.313